phrykt

Aclaris Therapeutics, Inc. (ACRS): who owns it and who trades it

As of Nov 16, 2026, ACRS insiders reported 1 open-market sale worth $1.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Braden Michael Leonard (10% owner), with $1.4M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aclaris Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ACRS

149 funds and institutions reported ACRS shares worth $643M at the end of Q2 2026, about 87% of the company. The largest holder is Ra Capital Management, L.P. with 9.1%.

Funds and institutions (13F) 87%Everyone else 13%

10 largest owners, by share of the company

Ra Capital Management, L.P.9.1%
BML Capital Management, LLC8.6%
BlackRock, Inc.7.2%
Deep Track Capital, LP6.7%
Vivo Capital, LLC4.8%
Vanguard Capital Management LLC4.2%
Frazier Life Sciences Management, L.P.3.5%
Rock Springs Capital Management LP3.1%
Adage Capital Partners Gp, L.l.c.2.9%
Decheng Capital LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.12.72M9.11%$67.3M+87%
BML Capital Management, LLC11.97M8.57%$63.3M-16%
BlackRock, Inc.10.04M7.19%$53.1M+36%
Deep Track Capital, LP9.35M6.69%$49.4MNo change
Vivo Capital, LLC6.69M4.79%$35.4M+0%
Vanguard Capital Management LLC5.82M4.17%$30.8M+13%
Frazier Life Sciences Management, L.P.4.93M3.53%$26.1MNo change
Rock Springs Capital Management LP4.33M3.10%$22.9M-3%
Adage Capital Partners Gp, L.l.c.4.07M2.91%$21.5M+5%
Decheng Capital LLC4.04M2.89%$21.4MNo change
Kalehua Capital Management LLC3.66M2.62%$19.4M+16%
State Street Corp3.26M2.33%$17.2M+62%
Geode Capital Management, LLC3.19M2.28%$16.9M+32%
Braidwell LP2.14M1.53%$11.3M+26%
Balyasny Asset Management L.P.2.02M1.45%$10.7M-40%
Silverarc Capital Management, LLC1.95M1.39%$10.3M–
Citadel Advisors LLC1.76M1.26%$9.3M-22%
Jones Hill Capital LP1.76M1.26%$9.3M–
Acadian Asset Management LLC1.64M1.18%$8.7M+7%
Palo Alto Investors LP1.61M1.16%$8.5MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ACRS insiders reported $0 of open-market purchases and $1.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.4M
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 23, 2026
Filed Apr 27, 2026

Purchases and sales by month

$1.4M$1.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 23, 2026Braden Michael Leonard10% ownerSale300,000$4.53$1.4MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Braden Michael Leonard10% owner–$1.4MApr 23, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ACRS short interest

Moderate short interest. 7.3% of ACRS shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 58%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.57M ACRS shares were sold short, 7.3% of the shares outstanding, down 23.0% from the report before. At the average daily volume of 2.88M shares, buying them all back would take about 4.0 trading days (days to cover).

Shares short, % of all shares

7.30%May 15Oct 3013.4%

Days to cover

4.0May 15Oct 309.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.57M7.30%-23%2.88M4.0
Oct 15, 202615.03M10.21%-17%5.10M3.0
Sep 30, 202618.19M12.36%+13%2.81M6.5
Sep 15, 202616.08M10.92%+6%2.52M6.4
Aug 31, 202615.18M10.31%+3%1.75M8.7
Aug 14, 202614.71M9.99%+7%2.10M7.0
Jul 31, 202613.77M9.36%+3%1.59M8.7
Jul 15, 202613.36M9.56%+17%1.93M6.9
Jun 30, 202611.40M8.17%+28%2.67M4.3
Jun 15, 20268.90M6.37%+10%1.31M6.8
May 29, 20268.08M5.78%+10%915,7238.8
May 15, 20267.35M5.26%-7%1.31M5.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aclaris Therapeutics company events

Aclaris Therapeutics filed 13 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 27, 2026AgreementAclaris Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share and… Filing
  3. Oct 27, 2026AnnouncementAclaris Therapeutics, Inc. issued a press release announcing primary analysis results from the Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma. Filing
  4. Aug 6, 2026AgreementAclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. under which the Company may offer and sell, from time to time at the Company’s sole discretion, shares of common stock through Leerink and Cantor as sales… Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jun 4, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 28, 2026AnnouncementThe Company issued a press release announcing the ATI-052 Results & ATI-2138 Trial. Filing
  9. Mar 11, 2026AnnouncementShared information with investors. Filing
  10. Mar 10, 2026AnnouncementShared information with investors. Filing
  11. Feb 26, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026AnnouncementShared information with investors. Filing
  13. Jan 6, 2026AnnouncementInterim Phase 1a SAD/MAD Results The Interim Results announced in the press release are summarized below. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Aclaris Therapeutics financials

Famous investors that hold ACRS

3 of the 50 well-known investors we track reported holding ACRS in their latest 13F filing. The largest position is Ken Griffin's, worth $9.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.78M$9.3M0.0%+1%
Jim Simons · Renaissance TechnologiesQ3 202682,812$436K0.0%-90%
Israel Englander · Millennium ManagementQ3 202650,673$267K0.0%-90%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ACRS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Biosion, Inc.13G/A4.7%
Nov 16, 2026Biosion, Inc.13G/A4.7%

Questions about Aclaris Therapeutics, Inc. (ACRS) stock

Who owns the most ACRS stock?

The largest reported owner of Aclaris Therapeutics, Inc. (ACRS) is Ra Capital Management, L.P., with 9.1% of the company. In total, 149 funds and institutions reported holding ACRS at the end of Q2 2026, together about 87% of the shares. See the largest owners.

Are ACRS insiders buying or selling?

In the last 12 months, ACRS insiders reported no open-market purchases and 1 sale worth $1.4M. The latest trade was on Apr 23, 2026. See every trade.

What is the short interest in ACRS?

As of Oct 30, 2026, 11.57M ACRS shares were sold short, 7.3% of the shares outstanding, down 23.0% from the report before. At the average daily volume of 2.88M shares, buying them all back would take about 4.0 trading days (days to cover). See the history.

Which famous investors hold ACRS?

3 of the 50 well-known investors we track reported ACRS in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $9.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.